ADRB2 and breast carcinoma: Epidemiological studies support the hypothesis that exposure to β2-AR antagonists may indeed reduce cancer progression and mortality, e.g., in melanoma (De Giorgi et al., 2011) and in breast cancer (Powe et al., 2010), although conflicting results have also been reported (Shah et al., 2011; Choi et al., 2014).